Navigation Links
New TB vaccine approach shows promise in mice
Date:9/6/2011

An experimental vaccine composed of a genetically modified bacterium closely related to the bacterium that causes tuberculosis (TB) has been found to protect mice against TB infection, according to a study appearing online September 4 in the journal Nature Medicine. The research was funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.

TB, a respiratory disease that according to World Health Organization estimates killed 1.7 million people worldwide in 2009, is caused by the bacterium Mycobacterium tuberculosis (Mtb). A vaccine to prevent TB infection, called bacille Calmette-Gurin (BCG), is widely available, but it confers limited protection and can cause severe TB infection in infants infected with HIV, restricting its use in certain countries.

In the new study, led by William R. Jacobs, Jr., Ph.D., of the Albert Einstein College of Medicine in New York, researchers genetically modified M. smegmatis, a relative of Mtb that is generally harmless to humans. Specifically, the scientists replaced a set of M. smegmatis genes called esx-3, believed to be important because its DNA sequence is unusually consistent across species, with the corresponding but not identical set of genes from Mtb. They vaccinated mice with this modified form of M. smegmatis, essentially delivering the Mtb version of esx-3 without the bacterial components that would cause infection, and then challenged the mice with Mtb. In mice that received the experimental vaccine, levels of TB bacteria were 1,000 times lower than in those that received BCG. This suggests that modified M. smegmatis induces a strong immune response in mice that can protect them from TB.

The study authors are encouraged by their study results, but they caution that further testing of the modified M. smegmatis TB vaccine is needed before it might be evaluated in human clinical trials.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. More U.S. Tweens Getting Recommended Vaccines
2. GEN reports on advances in DNA vaccine delivery and production
3. Single vaccines to protect against both rabies and Ebola
4. U.S.-Mandated Report Finds Vaccines Safe for Kids
5. Few health problems are caused by vaccines, IOM report finds
6. Kids Benefit From Flu Vaccine via Shot or Spray, Study Finds
7. Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines
8. Researchers create new experimental vaccine against chikungunya virus
9. New TB vaccine enters proof-of-concept trial in people living with HIV
10. Fine-tuning the flu vaccine for broader protection
11. Vaccine to Prevent Heroin High Works in Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: